Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 in moderate to severe forehead lines
NCT07730554Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
A Phase 2 trial of trenibotulinumtoxinE, sponsored by AbbVie Inc.. Started Jul 2026; status: active, not recruiting.
02
Drugs
trenibotulinumtoxinE
Beyond the preview
Go deeper on NCT07730554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730554.